viewInnoCan Pharma

Innocan Pharma reaches agreement to sell its CBD product lines in Germany

Innocan Pharma says its distribution agreement with German company iAmHealth Distribution UG is one of several such agreements it has signed in Europe

InnoCan Pharma -
Innocan Pharma believes iAmHealth will provide a premier distribution channel for its SHIR and Relief & Go product lines

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) announced Wednesday that its wholly-owned Israeli subsidiary has entered into a distribution agreement with German company iAmHealth Distribution UG, a CBD products provider, to sell Innocan’s SHIR Beauty and Relief & Go product lines in Germany.

iAmHealth will distribute Innocan's cosmetic CBD products on a non-exclusive basis, immediately following the completion of all registration and regulatory requirements in Germany.

Innocan Pharma CEO Iris Bincovich said in a statement: "We are excited to start our product distribution in Germany. This is one of several distribution agreements that we have signed in Europe. I believe iAmHealth will provide a premier distribution channel for our SHIR and Relief & Go product lines."

READ: Innocan Pharma says its R&G Relief & Go CBD Spray product successfully passes EU safety requirements

iAmHealths Managing Director Nina Wlodarczyk added: "Our iAmHealth team comes from the medical industry with research based on science. As cannabidiol (CBD) became more available and gained popularity in Germany, we wanted to make our contribution and create a place for all of our existing customers, as well as people who are looking for new products they can trust, and with a high level of efficacy. We believe Innocan, as a pharmaceutical oriented company, is the perfect fit to complement the range of our existing products that we offer to the German consumer."

Innocan’s R&G Relief & Go CBD Spray product has successfully passed detailed safety assessment requirements of the European Parliament and the Council on Cosmetic Products and has also has received a Cosmetic Product Safety Report (CPSR) for product marketing in the EU.

The company’s patent-pending unique formulation spray combines the known benefits of active ingredients, such as menthol and camphor, with CBD and magnesium (more than 40% in the formula) to help the body relax and recover for sport-performing professionals.

Contact Sean at sean@proactiveinvestors.com

Quick facts: InnoCan Pharma

Price: 0.41 CAD

Market: CSE
Market Cap: $72.04 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...


Innocan Pharma closes financing while launching new commercial website...

Innocan Pharma (CSE: INNO- OTCPINK: INNPF) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has launched a new consumer website for the sale of their products. The site is shop.innocanpharma.com Bincovich also told Proactive about their recent closing of their...

1 week, 5 days ago

2 min read